Find out Which Companies Are Best Positioned to Succeed in the Global Pain Market over the Period 2005-11.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38914) has announced the addition of The Pain Market Outlook to 2011 to their offering.

The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; across the seven major markets in 2005 it was estimated that 37.6m individuals suffered from neuropathic pain and 170.1m suffered from nociceptive pain.

The major constituents of the neuropathic pain market are lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain and pain associated with multiple sclerosis. The nociceptive pain market is driven by the prevalence of the major indications of arthritic pain, particularly osteoarthritis and rheumatoid arthritis, post-operative pain, cancer-related pain and HIV-related pain.

Current management of pain is mostly pharmacological consisting of the use of opioids, non-opioids and non-steroidal anti-inflammatory drugs (NSAIDs), as well as adjuvant therapies such as anti-depressants and anti-convulsants.

Although pain is not a new phenomenon, misdiagnosis and under-treatment continue to prove deleterious to the pain market. Increased education for patients, physicians, nurses and pharmacists is an on-going unmet need that must be addressed. Across the seven major markets, it is forecast that the prevalence of both the neuropathic and nociceptive markets will increase modestly. It is forecast that the prevalence of the neuropathic pain market will increase to 39.1m individuals, which is complimented by the forecast growth of the nociceptive market to include 164.8m individuals in 2011.

The Pain Market Outlook to 2011 provides in-depth insights into the key market and competitive dynamics in 8 major pain indications. This report's latest sales data and 6-year forecasts will enable you to benchmark the strategies behind the market leading products of today and predict how recent and upcoming product launches will be best positioned for growth.

Use this report to understand how changes in market dynamics will impact the competitive position of industry leaders over the period 2006-2011 and ensure you exploit emerging opportunities.

"Newron Pharmaceuticals SpA, an Italian research and development company focused on novel CNS therapies, is currently developing ralfinamide for the treatment of neuropathic pain. Ralfinamide is a novel compound of the alpha-aminoamide family with potent sodium channel blocker properties..."

Just some of the key findings of the report...

--Within the pain therapy market there remains a substantial unmet need for drugs with improved efficacy and superior side-effect profiles, however there are few novel drugs in the pipeline and companies are heavily dependent on reformulations of existing drugs targeting better drug delivery, more convenient dosing schedules and specific patient populations.

--Over the 2001-05 period, the global pain market expanded at a CAGR of 7.9%, accounting for a net growth in sales of $9,571m. While the pain market has experienced several years of continuous growth, over 2004-05 sales dropped by 7.0% due to the withdrawal from the market of COX-II inhibitors, Vioxx and Bextra for safety reasons. Sales in this drug class plummeted by 66.2% in 2005.

--Currently the pain market is led by the anti-convulsant class, hich accrued sales of $11,574m in 2005 with the majority of revenue being derived from off-label use. Although the anti-convulsant class will maintain its leading position through 2010, future growth in the pain market will be driven by a small number of blockbuster drugs and the re-uptake of COX-II inhibitors

--Pfizer's current dominance of the pain market is forecast to continue through 2011 due to the evolving success of its blockbuster drug, Celebrex and the recent launch of Lyrica, which promises market success comparable to its predecessor, Neurontin.

"The most prevalent tumor-related nociceptive cancer pain syndrome is bone pain. The spine is the most common site of bone metastases, which results in back pain as a highly prevalent problem among cancer sufferers..."

Key questions answered in this report

--Which new compounds are forecast to gain rapid market penetration and which indications are forecast to see the greatest levels of development from new therapies?

--How have recent patent expiries affected blockbuster brands such as Duragesic, Ultram, OxyContin, and Celebrex?

--Which products were the key performers in the pain market in 2005 and what were the factors underpinning their performance?

--Which companies are best positioned to succeed in the global pain market over the period 2005-11 and why?

--How will the composition of the pain market change over the period 2005-2011 and how will recent and future events affect the major drug classes?

--How have the withdrawals of Cox-II inhibitors, Vioxx and Bextra, impacted the pain market at a brand, drug class and company level?

"Novartis' Prexige, a highly selective COX-II inhibitor, is indicated for the treatment of OA, RA, pain and dysmenorrhea. Prexige has managed to differentiate itself from existing COX-II inhibitors that have been withdrawn from the market due to an associated risk of adverse cardiovascular events..."

Top five reasons to order your copy today:

1. Identify the pain indications with the greatest growth prospective and key factors impacting their prevalence, enabling you to align your portfolio to meet patient needs.

2. Understand how recent events are affecting the performance of major products and discover how their marketers are confronting competitive changes in the pain marketplace.

3. Gain a competitive edge, identify your main competitors and discover critical success factors, ensuring you are up-to-date with market developments and can exploit emerging opportunities.

4. Analyze up-to-date global IMS sales data with comprehensive information on current marketed products and key brands, allowing you to assess your organization's position in the competitive market-place.

5. Predict future top selling products by examining detailed product forecasts, future patent expiries and current innovation in the pain market.

"Opioids, widely used in the treatment of multiple forms of pain, accrued $8,311m in sales during 2005, an increase of 2.5% over previous year sales of $8,109m. Opioids continue to form the mainstay of severe pain therapy, but with levels of new product introductions being low, the class as a whole is struggling to generate significant levels of sales growth against a background of generic competition..."

Topics Covered

The Pain Market Outlook to 2011

Executive Summary

Patient potential

Global market analysis

Analysis of potential future blockbusters

Leading players in the global pain market

Chapter 1 Patient potential

Chapter 2 Global market analysis

Chapter 3 Analysis of potential future

Chapter 4 Leading players in the global pain

Chapter 5 Appendix

List of Figures

List of Tables

Drugs Mentioned Include:

- NW-1029 (ralfinamide) - Tapentadol (CG5503/R33133) - Bicifadine - Transacin (NGX-4010) - Neurodex (dectromorphan/quinidine) - Chronogesic (sufentanil) - Lacosamide - M6G (morphine-6-glucuronide) - Licofelone (ML3000) - Lyrica (pregabalin) - Prialt (ziconotide) - IONSYS (fentanyl iontophoretic transdermal system) - DepoDur (morphine) - Prexige (lumiracoxib)

Companies Mentioned Include:

- Pfizer - Johnson & Johnson - Novartis - GlaxoSmithKline - Mundipharma Int. - Abbott - Boehringer Ingelheim - Sanofi-Aventis

For more information visit http://www.researchandmarkets.com/reports/c38914